Replimune Group Inc.

Replimune Group Inc. is not a good growth stock. Replimune Group Inc. is not very popular among insiders. Replimune Group Inc. is a mediocre stock to choose.
Log in to see more information.
Replimune Group, Inc. is a clinical-biotechnology company, which engages in the development of oncol...
REPL Fundamental Data by TradingView

News

Replimune Group (NASDAQ:REPL) Rating Reiterated by HC Wainwright
Replimune Group (NASDAQ:REPL) Rating Reiterated by HC Wainwright

Zolmax Replimune Group (NASDAQ:REPL - Get Free Report)s stock had its "buy" rating reaffirmed by equities researchers at HC Wainwright in a report released on Tuesday, Benzinga reports. They...\n more…

Replimune Group (NASDAQ:REPL) Earns Buy Rating from HC Wainwright
Replimune Group (NASDAQ:REPL) Earns Buy Rating from HC Wainwright

Ticker Report HC Wainwright reiterated their buy rating on shares of Replimune Group (NASDAQ:REPL - Free Report) in a report released on Tuesday, Benzinga reports. The firm currently has a $17.00 price target on...\n more…

Zurcher Kantonalbank Zurich Cantonalbank Sells 3,497 Shares of Replimune Group, Inc. (NASDAQ:REPL)
Zurcher Kantonalbank Zurich Cantonalbank Sells 3,497 Shares of Replimune Group, Inc. (NASDAQ:REPL)

Ticker Report Zurcher Kantonalbank Zurich Cantonalbank cut its holdings in Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 38.7% in the second quarter, according to the company in its most recent Form 13F...\n more…

Brokerages Set Replimune Group, Inc. (NASDAQ:REPL) PT at $16.20
Brokerages Set Replimune Group, Inc. (NASDAQ:REPL) PT at $16.20

Zolmax Shares of Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) have earned a consensus rating of "Buy" from the six ratings firms that are presently covering the company, Marketbeat Ratings...\n more…

Analysts Set Replimune Group, Inc. (NASDAQ:REPL) Price Target at $16.20
Analysts Set Replimune Group, Inc. (NASDAQ:REPL) Price Target at $16.20

Ticker Report Shares of Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) have been assigned an average recommendation of "Buy" from the six research firms that are currently covering the firm, Marketbeat...\n more…

Analysts Set Expectations for Replimune Group, Inc.'s Q2 2025 Earnings (NASDAQ:REPL)
Analysts Set Expectations for Replimune Group, Inc.'s Q2 2025 Earnings (NASDAQ:REPL)

Ticker Report Replimune Group, Inc. (NASDAQ:REPL - Free Report) - Investment analysts at Roth Capital issued their Q2 2025 earnings estimates for shares of Replimune Group in a report released on Tuesday, August...\n more…